MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

Background: MCLA-129, a novel human, EGFR/c-MET bispecific antibody, demonstrates anti-tumor activities in EGFR and/or c-MET driven tumor models via multiple mechanisms, including inhibition of ligand binding, receptor co-degradation, antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis. MCLA-129 is being investigated in patients (pts) with advanced solid tumors in an ongoing First in Human study (NCT04868877). EGFR and c-MET are frequently mutated or overexpressed in epithelial tumors, driving ligand-independent receptor activation.